-
Andera Partners has supported Agomab company since the Series A in 2019, investing meaningfully in the company’s subsequent financing rounds and helping Agomab to become a prominent European biotech with headquarters in Belgium.
-
This marks the third public listing in the BioDiscovery portfolio in the last 12 months (after Kestra in March 2025 and Evommune in November 2025) and adds to our recent string of good news including ImCheck’s €1B acquisition by Ipsen and Tubulis’ record-setting financing round for a European biotechnology company at the end of last year.
Andera Partners announced today that Agomab, one of its portfolio companies, has completed a $200 million initial public offering on the NASDAQ stock market. The Company is trading under the ticker AGMB and it made its public market debut on February 6th.
Funds raised from the offering will support clinical advancement of ontunisertib, the company’s lead clinical-stage candidate—a GI-restricted ALK5 inhibitor in Phase 2 development for Fibrostenosing Crohn’s Disease—alongside AGMB-447, which is undergoing Phase 1 evaluation for Idiopathic Pulmonary Fibrosis.
Jan Van den Bossche, Partner at Andera Partners, added: “Agomab’s journey from the Series A in 2019 to the remarkable Nasdaq IPO exemplifies the kind of consistent value creation we seek to support at Andera Partners. Completing a $200 million IPO in the current volatile capital markets environment is particularly remarkable for a European biotech. It is also a testament to the quality of both the science and the team behind it, benefiting from the strong Belgian biotech ecosystem. As an early investor in the company, we’ve witnessed the caliber of this management team and their ability to execute on an ambitious clinical roadmap. The therapeutic programs they’ve advanced hold genuine promise to transform treatment options for patients facing conditions with limited alternatives, and we’re excited to follow them in this next chapter.”